SUMMARY
Acetaminophen, Caffeine and Dihydrocodeine Bitartrate* Tablets CIII
.8 mg/60 mg/32 mg
Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets are supplied in tablet form for oral administration.
Each tablet contains:
Acetaminophen..........................................................712.8 mg
Caffeine.....................................................................60 mg
Dihydrocodeine Bitartrate*..........................................32 mg
(*Warning: May be habit forming)
Acetaminophen (4'-hydroxyacetanilide), a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic.
Caffeine (1,3,7-trimethylxanthine), a bitter, white powder or white-glistening needles, is a central nervous system stimulant.
Dihydrocodeine bitartrate (4,5á-Epoxy-3-methoxy-17-methylmorphinan-6á-ol (+)-tartrate), an odorless, fine white powder is an opioid analgesic.
Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets are indicated for the relief of moderate to moderately severe pain.
|
NEWS HIGHLIGHTSMedia Articles Related to Acetaminophen, Caffeine and Dihydrocodeine (Acetaminophen / Caffeine / Dihydrocodeine)
62-Year-Old Man Becomes First Patient In China Implanted With Rechargeable Neurostimulator For Chronic Pain
Source: Health News from Medical News Today [2009.11.19]
St. Jude Medical, Inc. (NYSE:STJ) announced that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.
Common Pain Relief Medication May Encourage Cancer Growth
Source: Cancer / Oncology News From Medical News Today [2009.11.19]
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Two new studies advance that argument and demonstrate how shielding lung cancer cells from opiates reduces cell proliferation, invasion and migration in both cell-culture and mouse models.
CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference In San Francisco
Source: Clinical Trials / Drug Trials News From Medical News Today [2009.11.19]
CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA. Dr.
Transplanting People's Own Stem Cells Into Heart Lessens Pain, Improves Ability To Walk
Source: Clinical Trials / Drug Trials News From Medical News Today [2009.11.19]
The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.
FDA Approves New Drug For Pain That Persists After Shingles
Source: Dermatology News From Medical News Today [2009.11.18]
The US Food and Drug Administration (FDA) announced yesterday that it has approved Qutenza (capsaicin) 8% patch for the treatment of post-herpetic neuralgia (PHN), an often excruciating pain that can persist for weeks, months and even years in 10 to 15 per cent of people who get shingles. The medicated skin patch, which is made by Lohmann Therapie-Systems AD of Andernach, Germany and distributed in the US by NeurogesX Inc.
Clinical Trials Related to Acetaminophen, Caffeine and Dihydrocodeine (Acetaminophen / Caffeine / Dihydrocodeine)
Acetaminophen for Cancer Pain [Recruiting]
Many patients with cancer pain have pain not fully controlled on opioids (eg. morphine).
The addition of acetaminophen (Tylenol) to opioids in a small study in cancer patients
demonstrated better pain control without an increase in side effects. This study will
determine if regular acetaminophen improves pain control when added to strong opioids in
patients with cancer pain.
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) [Recruiting]
A non-randomized, open-label study to investigate the effects of imatinib mesylate on the
pharmacokinetics of acetaminophen/paracetamol in patients with newly diagnosed, previously
untreated chronic myeloid leukemia in chronic phase (CML-CP)
A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament [Completed]
The purpose of this study is to explore the pain-relieving effects and safety of two
analgesic treatment regimens as compared to placebo in patients experiencing acute
musculoskeletal pain. Patients who are experiencing at least moderate acute musculoskeletal
pain from an ankle sprain severe enough to require prescription pain relief medication will
be randomized to receive either tramadol HCl/acetaminophen, hydrocodone
bitartrate/acetaminophen or placebo.
AVIS - Acetaminophen Before Vaccines for Infants Study [Recruiting]
The purpose of this study is to see whether giving acetaminophen (the medicine in Tylenol)
for routine infant vaccinations is helpful in preventing fever or other symptoms.
A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery [Completed]
Increasingly in general surgery, the investigators are conducting outpatient day surgery.
Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America.
These patients all require some form of analgesia which can be taken at home in the first few
days after the surgery. The current standard at the investigators' centre and many others in
the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or
oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as
oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication
(Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects,
and may not provide effective pain relief. In the investigators' experience, non-steroidal
anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic
regimen.
Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain
medication. They hope to show that a combination of ibuprofen and acetaminophen is better for
pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a
safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of
surgeons are old habits, it will require a very convincing argument to get them to change
their practices. A randomized controlled trial comparing these two regimens, the
investigators hope, would be a powerful enough argument.
The hypothesis of this study, therefore, is that the pain control provided by a combination
of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to
Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day).
This study will attempt to enroll 150 patients in total. Eligible patients will be identified
by their attending surgeon and contacted by study personnel. Patients who enroll in the study
will undergo their surgery in the usual manner. After the surgery, in the recovery room, once
they are ready to go home, they will be randomized to receive combination A or B and be given
a week's worth of pain medication. They will then go home and take this medication as
directed. They will record their pain intensity and pain relief once per day using a diary
provided in the study package. One week after their surgery, they will return to the hospital
clinic and be seen by the study nurse. They will hand over the diary and any unused
medication. They will also be asked several questions regarding their overall satisfaction,
incidence of side effects, and how long until they were pain free.
The risks of participating in this study are minimal from the risks inherent to the
procedures and medications the patients would receive within the standard of care. Ibuprofen
is a commonly used NSAID which is widely available over the counter and has an established
safety profile. The most common adverse effects of ibuprofen and other NSAIDs are
gastrointestinal bleeding and ulceration. Other less common adverse effects include
nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive
dysfunction. The investigators' patients will be selected to exclude those most at risk for
these complications (see exclusion criteria). Acetaminophen has few side effects, with no
adverse effects on platelet function and no evidence of gastric irritation.
|
|
|
|
Page last updated: 2009-11-19
|
